Skip to main content
Chongqing Pharscin Pharmaceutical Co., Ltd. logo

Chongqing Pharscin Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002907 ISIN · CNE100003308 LEI · 300300M2F5XMGFAYMA24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2026-04-23 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 002907

About Chongqing Pharscin Pharmaceutical Co., Ltd.

https://www.pharscin.com

Chongqing Pharscin Pharmaceutical Co., Ltd. is an integrated enterprise specializing in the research, development, production, and commercialization of chemical drugs and modern traditional Chinese medicine. The company focuses on therapeutic areas such as digestive system health, cardiovascular and cerebrovascular diseases, and hepatobiliary conditions. Its portfolio includes a variety of proprietary formulations and generic medications, notably treatments for chronic liver disease and gastrointestinal disorders. Pharscin maintains advanced manufacturing facilities and a dedicated R&D infrastructure focused on enhancing drug efficacy and delivery systems. The organization emphasizes clinical value and technological innovation to provide comprehensive healthcare solutions across diverse medical sectors.

Recent filings

Filing Released Lang Actions
2025年年度报告摘要
Annual Report Classification · 90% confidence The document is titled “2025年年度报告摘要” for 重庆华森制药股份有限公司 and contains a comprehensive overview of business operations, product lines, R&D activities, detailed financial results (income, profit, cash flows), quarterly and annual accounting data, shareholding tables, and management discussion and analysis. It is not merely a notice that a report has been published, but the actual Annual Report summary itself. This aligns with the definition of an Annual Report (10-K) covering company activity and full financial performance. FY 2025
2026-04-23 Chinese
2025年度内部控制自我评价报告
Regulatory Filings Classification · 70% confidence The document is a standalone internal control self-evaluation report for the fiscal year ending December 31, 2025, issued by 重庆华森制药股份有限公司’s board and audit committee. It is not an AGM presentation, earnings release, or full annual/interim report, nor does it announce the publication of another report. It details regulatory compliance and internal control systems and their evaluation results. There is no specific category for internal control self-evaluation, so it should be classified as a general regulatory filing (RNS).
2026-04-23 Chinese
关于“质量回报双提升”行动方案的进展公告
Regulatory Filings Classification · 80% confidence The document is a corporate announcement detailing progress on a previously disclosed strategic “quality return dual improvement” action plan, covering R&D milestones, governance updates, and dividend distribution proposals. It does not present formal financial statements as in an interim report, nor is it a standalone earnings release, management change notice, or detailed report publication announcement. This makes it fall into the general regulatory announcement category (Regulatory Filings, RNS).
2026-04-23 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 85% confidence The document is a general announcement (公告) by a listed company concerning changes in accounting policies under a new Ministry of Finance interpretation. It contains no financial statements or numeric results, nor is it a report of a shareholder vote, dividend notice, M&A, or board/management change. It is not presenting the actual annual or interim report, nor is it a presentation or supplement. Instead, it is a standard regulatory disclosure of an accounting policy change, falling into the catch-all category for miscellaneous compliance filings. Therefore, the correct classification is Regulatory Filings (RNS).
2026-04-23 Chinese
关于向银行申请综合授信额度的公告
Capital/Financing Update Classification · 90% confidence The document is a formal announcement by the pharmaceutical company regarding its board-approved plan to apply for a comprehensive bank credit facility of up to RMB 3 billion, including details on the credit types, authorization, and terms. There is no discussion of equity issuance or share transactions, nor is it an annual or quarterly financial report. This is clearly a financing activity update (debt credit facilities), fitting the Capital/Financing Update category.
2026-04-23 Chinese
关于公司2026年度董事、高级管理人员薪酬方案的公告
Remuneration Information Classification · 90% confidence The document is an official announcement by the board of Chongqing Huashen Pharmaceutical detailing the 2026 remuneration scheme for directors and senior management, including salary standards and performance pay structure. It is not a full annual or interim report, nor a governance charter, but specifically outlines executive compensation. This corresponds to Remuneration Information (DEF 14A).
2026-04-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.